Italfarmaco licenses JCR’s Hunter syndrome therapy JR-141 for US, Europe, Latin America commercialization
Bitget2026/10/02 06:30- JCR Pharmaceuticals signed an exclusive license deal with Italfarmaco to develop JR-141 for Hunter syndrome in the US, Europe, Latin America.
- Italfarmaco receives exclusive commercialization rights in the licensed territories, contingent on regulatory approvals.
- JCR keeps manufacturing responsibility; deal includes upfront, milestone, royalty payments, plus supply revenue.
- JR-141 is a blood-brain barrier–penetrating enzyme replacement therapy; JCR is running a global Phase III trial.
- Upfront payment was incorporated into JCR’s earnings forecast for the fiscal year ending March 31, 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Besent “Extinguishes Fire”: Rising US Treasury yields are a global phenomenon, dismisses concerns over AI bubble
U.S. Treasury Secretary Janet Yellen defended the rise in U.S. Treasury yields, stating that this increase is a global phenomenon rather than unique to the United States, and does not warrant excessive concern. She partially attributed inflationary pressures to higher oil prices caused by the Iran conflict, and expects the energy shock to subside as hostilities ease. Yellen refuted the notion of an AI bubble, arguing that investments by major tech companies are grounded in solid business logic.